Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease II: Ulcerative Colitis

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors.

Vaccine·2009

Same author

Fast generation of dendritic cells.

Cellular immunology·2009

Same author

Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells.

Clinical and experimental immunology·2009

Same author

Genome-wide gene expression profiling of SCID mice with T-cell-mediated Colitis.

Scandinavian journal of immunology·2009

Same author

Modified human beta 2-microglobulin (desLys(58)) displays decreased affinity for the heavy chain of MHC class I and induces nitric oxide production and apoptosis.

Scandinavian journal of immunology·2009

Same author

High-affinity human leucocyte antigen class I binding variola-derived peptides induce CD4+ T cell responses more than 30 years post-vaccinia virus vaccination.

Clinical and experimental immunology·2009

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Future targets for immune therapy in colitis?

N N Kristensen¹, M H Claesson

¹Department of International Health, Immunology and Microbiology, Panum Institute, building 18.3.52, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark. nannak@sund.ku.dk

Endocrine, Metabolic & Immune Disorders Drug Targets

|December 17, 2008

Summary

This summary is machine-generated.

Inflammatory bowel disease (IBD) involves gut inflammation driven by immune responses. Targeting chemokines and regulatory T cells (Tregs) offers promising therapeutic strategies for IBD treatment.

More Related Videos

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Related Experiment Videos

Last Updated: Jun 27, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Area of Science:

Immunology
Gastroenterology
Molecular Biology

Background:

Inflammatory bowel disease (IBD), including Crohn's disease and Ulcerative Colitis, is characterized by chronic gut inflammation.
The immune system's response to gut bacteria, particularly CD4+ T cells, plays a key role in IBD pathology.
Chemokines are crucial for immune cell migration in gut inflammation, making them potential therapeutic targets.

Purpose of the Study:

To review potential immune targets for treating colitis, a model for IBD.
To explore the role of chemokines and regulatory T cells (Tregs) in IBD pathogenesis and treatment.

Main Methods:

Utilized a severe combined immunodeficiency (SCID) transfer model of colitis.
Transplanted CD4+CD25- T cells into immune-deficient mice to induce colitis.
Investigated the suppressive effect of simultaneously transplanting CD4+CD25+ regulatory T cells (Tregs) on colitis development.

Main Results:

The SCID transfer model effectively replicates human IBD histopathology.
CD4+CD25- T cells induce chronic, lethal colitis in immune-deficient hosts.
The addition of CD4+CD25+ regulatory T cells (Tregs) prevents the development of colitis.

Conclusions:

The chemokine/receptor system is a viable target for IBD therapies aimed at maintaining remission.
Regulatory T cells (Tregs) play a critical role in suppressing gut inflammation.
Further research into immune targets like chemokines and Tregs is essential for developing novel IBD treatments.